MS drug interaction study: will common meds change tolebrutinib levels?
NCT ID NCT06064539
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study tested how two common drugs—gemfibrozil (for cholesterol) and rifampicin (an antibiotic)—affect the levels of tolebrutinib, an experimental oral drug for multiple sclerosis. Thirty healthy men aged 18 to 45 took tolebrutinib alone and then with each other drug. The goal was to see if these interactions require dose adjustments, not to test tolebrutinib's effectiveness or safety in MS patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tolebrutinib (SAR442168)
What this could lead to
If successful, this study could help doctors understand how to adjust tolebrutinib dosing when taken with other common drugs.
What could go wrong
This is a very early, small study in healthy volunteers, not people with MS. It only looks at drug levels, not whether the drug works or is safe long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Prism Research-Site Number:8400001
Saint Paul, Minnesota, 55144, United States